These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 17614352

  • 1. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
    Rocha A, Azevedo I, Soares R.
    J Cell Biochem; 2008 Feb 01; 103(2):607-14. PubMed ID: 17614352
    [Abstract] [Full Text] [Related]

  • 2. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells.
    Rocha A, Azevedo I, Soares R.
    Angiogenesis; 2007 Feb 01; 10(4):279-86. PubMed ID: 17876712
    [Abstract] [Full Text] [Related]

  • 3. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Brama M, Basciani S, Cherubini S, Mariani S, Migliaccio S, Arizzi M, Rosano G, Spera G, Gnessi L.
    Endocr Relat Cancer; 2007 Mar 01; 14(1):61-72. PubMed ID: 17395975
    [Abstract] [Full Text] [Related]

  • 4. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 5. Elucidating progesterone effects in breast cancer: cross talk with PDGF signaling pathway in smooth muscle cell.
    Soares R, Guerreiro S, Botelho M.
    J Cell Biochem; 2007 Jan 01; 100(1):174-83. PubMed ID: 16888808
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD, Rotunno S, Riedel F, Anders C, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.
    Int J Oncol; 2011 Apr 01; 38(4):1001-12. PubMed ID: 21249316
    [Abstract] [Full Text] [Related]

  • 7. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, Yang B.
    Basic Clin Pharmacol Toxicol; 2009 Mar 01; 104(3):241-52. PubMed ID: 19159435
    [Abstract] [Full Text] [Related]

  • 8. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Mar 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 9. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N.
    Differentiation; 2007 Nov 01; 75(9):843-52. PubMed ID: 17999742
    [Abstract] [Full Text] [Related]

  • 10. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ, Vanderhyden BC.
    Gynecol Oncol; 2007 Apr 01; 105(1):122-31. PubMed ID: 17169414
    [Abstract] [Full Text] [Related]

  • 11. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration.
    Popow-Woźniak A, Woźniakowska A, Kaczmarek L, Malicka-Błaszkiewicz M, Nowak D.
    Eur J Pharmacol; 2011 Sep 30; 667(1-3):66-73. PubMed ID: 21658383
    [Abstract] [Full Text] [Related]

  • 12. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A.
    Carcinogenesis; 2006 Mar 30; 27(3):664-71. PubMed ID: 16357008
    [Abstract] [Full Text] [Related]

  • 13. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.
    J Cell Biochem; 2008 Feb 01; 103(2):624-35. PubMed ID: 17562544
    [Abstract] [Full Text] [Related]

  • 14. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K.
    Int J Oncol; 2005 Jan 01; 26(1):33-40. PubMed ID: 15586222
    [Abstract] [Full Text] [Related]

  • 15. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN, Karamanos NK.
    FEBS J; 2013 May 01; 280(10):2477-89. PubMed ID: 23374223
    [Abstract] [Full Text] [Related]

  • 16. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines.
    Brown RE, Lun M, Prichard JW, Blasick TM, Zhang PL.
    Ann Clin Lab Sci; 2004 May 01; 34(3):251-62. PubMed ID: 15487699
    [Abstract] [Full Text] [Related]

  • 17. Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells.
    Pirraco A, Coelho P, Rocha A, Costa R, Vasques L, Soares R.
    J Cell Biochem; 2010 Oct 01; 111(2):433-41. PubMed ID: 20518073
    [Abstract] [Full Text] [Related]

  • 18. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E.
    Exp Oncol; 2007 Jun 01; 29(2):126-31. PubMed ID: 17704745
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V, Karampinas T, Voutsinas G, Roussidis AE, Papadopoulos S, Karamanos NK, Kletsas D.
    Mol Cancer Res; 2008 May 01; 6(5):706-14. PubMed ID: 18505916
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.